相似文献
1
Tumor suppression and normal aging in mice with constitutively high p53 activity.
Genes Dev. 2006 Jan 1;20(1):16-21. doi: 10.1101/gad.1378506.
2
The Dysfunctional MDM2-p53 Axis in Adipocytes Contributes to Aging-Related Metabolic Complications by Induction of Lipodystrophy.
Diabetes. 2018 Nov;67(11):2397-2409. doi: 10.2337/db18-0684. Epub 2018 Aug 21.
3
Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish.
Oncogene. 2015 Nov 26;34(48):5933-41. doi: 10.1038/onc.2015.57. Epub 2015 Mar 9.
4
Distinct downstream targets manifest p53-dependent pathologies in mice.
Oncogene. 2016 Nov 3;35(44):5713-5721. doi: 10.1038/onc.2016.111. Epub 2016 Apr 11.
5
TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Mol Cancer Res. 2008 Jan;6(1):64-77. doi: 10.1158/1541-7786.MCR-07-0005.
6
Tumor suppression by p53 without accelerated aging: just enough of a good thing?
Cell Cycle. 2006 Apr;5(7):714-7. doi: 10.4161/cc.5.7.2632. Epub 2006 Apr 1.
7
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Mol Cell Biol. 2007 Aug;27(15):5479-85. doi: 10.1128/MCB.00555-06. Epub 2007 May 25.
8
Relevance of the p53-MDM2 axis to aging.
Cell Death Differ. 2018 Jan;25(1):169-179. doi: 10.1038/cdd.2017.187. Epub 2017 Dec 1.
9
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Mol Cell Biol. 2007 Feb;27(3):1056-68. doi: 10.1128/MCB.01307-06. Epub 2006 Nov 20.
10
RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression.
Cancer Res. 2016 Sep 1;76(17):5030-9. doi: 10.1158/0008-5472.CAN-15-3420. Epub 2016 Jul 11.
引用本文的文献
1
ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice.
Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03352-w.
2
A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.
Cancers (Basel). 2025 Feb 13;17(4):626. doi: 10.3390/cancers17040626.
3
Characterization of an Hypomorphic Allele in a Diethylnitrosamine-Induced Liver Carcinogenesis Model.
Cancers (Basel). 2023 Sep 16;15(18):4596. doi: 10.3390/cancers15184596.
4
Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis.
Int J Mol Sci. 2023 Apr 11;24(8):7076. doi: 10.3390/ijms24087076.
5
Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program.
Cell Death Differ. 2023 Apr;30(4):897-905. doi: 10.1038/s41418-023-01123-2. Epub 2023 Feb 8.
6
How can aging be reversed? Exploring rejuvenation from a damage-based perspective.
Adv Genet (Hoboken). 2020 Aug 10;1(1):e10025. doi: 10.1002/ggn2.10025. eCollection 2020 Dec.
7
MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging.
Biology (Basel). 2022 Jun 8;11(6):881. doi: 10.3390/biology11060881.
8
Partial p53 reactivation is sufficient to induce cancer regression.
J Exp Clin Cancer Res. 2022 Mar 2;41(1):80. doi: 10.1186/s13046-022-02269-6.
9
Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo.
Cancer Res. 2022 Apr 1;82(7):1313-1320. doi: 10.1158/0008-5472.CAN-21-2381.
10
p53 partial loss-of-function mutations sensitize to chemotherapy.
Oncogene. 2022 Feb;41(7):1011-1023. doi: 10.1038/s41388-021-02141-5. Epub 2021 Dec 14.
本文引用的文献
1
p53 isoforms can regulate p53 transcriptional activity.
Genes Dev. 2005 Sep 15;19(18):2122-37. doi: 10.1101/gad.1339905. Epub 2005 Aug 30.
2
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Cancer Cell. 2005 Jun;7(6):547-59. doi: 10.1016/j.ccr.2005.04.029.
3
Hereditary colorectal cancer syndromes.
Cancer Causes Control. 2005 Apr;16(3):201-13. doi: 10.1007/s10552-004-3488-4.
4
Complicating the role of p53 in aging.
Aging Cell. 2005 Jun;4(3):157-60. doi: 10.1111/j.1474-9726.2005.00154.x.
5
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Cell. 2004 Nov 24;119(5):591-602. doi: 10.1016/j.cell.2004.11.022.
6
Turning the key on p53.
Nature. 2004 Feb 26;427(6977):789-90. doi: 10.1038/427789a.
7
Modulation of mammalian life span by the short isoform of p53.
Genes Dev. 2004 Feb 1;18(3):306-19. doi: 10.1101/gad.1162404.
8
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004 Jan 2.
9
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses.
J Biol Chem. 2003 Oct 17;278(42):41028-33. doi: 10.1074/jbc.M306938200. Epub 2003 Aug 8.
10
mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.
Mol Cell Biol. 2003 Jan;23(2):462-72. doi: 10.1128/MCB.23.2.462-473.2003.
Zotero 插件